Region Skåne extends agreement with Bactiguard

In 2017 Bactiguard signed a framework agreement with Region Skåne, which enables both county councils and municipalities to order Bactiguard's infection prevention urinary catheters. The initial contract expires on April 30th,  2018 and now Region Skåne chooses to extend the agreement for another year until April 30th, 2019.

"The demand for our products continues to increase and we receive good feedback from both patients and healthcare professionals. In Region Skåne, a patient survey was conducted where permanent users after a trial period could choose if they wanted to continue with their previous catheter or switch to Bactiguard, and I am happy to say that
90 % chose us, "says Nina Nilsson, SVP Sales and Marketing at Bactiguard.

The agreement is valid from 2017 and can be renewed on an annual basis until 2020, and Region Skåne now chooses to use the first extension right until April 30, 2019. It covers Bactiguard's BIP Foley Catheter Silicone in a number of common sizes, a product evaluated in the region for a long time.

For further information, please contact:

Nina Nilsson, SVP Sales and Marketing, Mobile: +46 70 214 87 49

About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 60 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives on www.bactiguard.com